Drugs by condition
Drugs approved for hemophilia
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
7
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
4
New molecular entities and new biologics
In development
19
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for hemophilia.
- Qfitlia (Fitusiran Sodium) · Genzyme Corp NovelOrphanMar 28, 2025
- Alhemo (Concizumab-Mtci) · Novo Nordisk INC NovelPriority reviewOrphanDec 20, 2024
- Hympavzi (Marstacimab-Hncq) · Pfizer INC NovelOrphanOct 11, 2024
- Tranexamic Acid (Tranexamic Acid) · Exela Pharma Apr 15, 2019
- Hemlibra (Emicizumab) · Genentech INC NovelBreakthrough therapyPriority reviewOrphanNov 16, 2017
All approved drugs for hemophilia, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 26 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Antifibrinolytic Agent (2)
- Tranexamic Acid Tranexamic Acid · Exela Pharma · 2019
- Cyklokapron Tranexamic Acid · Pfizer · 1986
Antithrombin-directed RNA Interaction (1)
- Qfitlia Fitusiran Sodium · Genzyme Corp · 2025
Tissue Factor Pathway Inhibitor Antagonist (1)
- Alhemo Concizumab-Mtci · Novo Nordisk INC · 2024
Class not listed in FDA's data (3)
Drugs in development for hemophilia
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- KN057Phase 34 trials
Suzhou Alphamab Co., Ltd. · Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor, Hemophilia a and B
- SR604Phase 34 trials
Shanghai RAAS Blood Products Co., Ltd. · Factor VII Deficiency, Hemophilia A, Hemophilia B
- BIVV001efanesoctocog, AltuvoctPhase 33 trials
Swedish Orphan Biovitrum · Haemophilia A (Moderate or Severe), Hemophilia A, Hemophilia A, Severe
- bypassing agentsClotting factor concentrates, CFCPhase 33 trials
Sanofi · Hemophilia, Von Willebrand Disease, Type 3
- FRSW107Phase 33 trials
Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Severe Hemophilia A
- GS1191-0445Phase 32 trials
Gritgen Therapeutics Co., Ltd. · Severe Hemophilia A, Hemophilia A
- NXT007Zemocimig, RO7589655Phase 32 trials
Roche (Genentech) · Hemophilia A
- Valoctocogene roxaparvovecBMN 270, GENEr8Phase 32 trials
BioMarin · Hemophilia A, Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
- FRSW117Recombinant human coagulation factor Ⅷ-Fc fusion proteinPhase 31 trial
Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Severe Hemophilia A
- PF-06838435fidanacogene elaparvovecPhase 31 trial
Pfizer · Hemophilia B
- SKP-0141Phase 31 trial
SK Plasma Co., Ltd. · Hemophilia A, Severe
- STSP-0601Phase 31 trial
Jiangsu BioJeTay Biotechnology Co., Ltd. · Hemophilia
- ARD001Phase 21 trial
Arditus Pte Ltd · Hemophilia A, Healthy Adult Participants
- ASC618Phase 21 trial
ASC Therapeutics · Hemophilia A
- AskBio009BAX 335Phase 21 trial
Takeda · Hemophilia B
- BAY2599023DTX201Phase 21 trial
Bayer · Hemophilia A
- LNP1265Phase 21 trial
Regeneron · Hemophilia B
- REGV131Phase 21 trial
Regeneron · Hemophilia B
- SPK-8011QQRO7878488Phase 21 trial
Roche (Genentech) · Hemophilia A
1 discontinued brand-name drugs whose label still names it
- Stimate Desmopressin Acetate
More on hemophilia: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.